Therapies for osteoarthritis today and tomorrow: Review
Osteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying&quo...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
2020-01-01
|
Series: | Scripta Medica |
Subjects: | |
Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003181S.pdf |
id |
doaj-2eb0d78d8ee848acacefaa3d3d1f056a |
---|---|
record_format |
Article |
spelling |
doaj-2eb0d78d8ee848acacefaa3d3d1f056a2020-11-25T04:00:25ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542020-01-015131811892490-33292003181STherapies for osteoarthritis today and tomorrow: ReviewSkrepnik Nebojša0Tucson Orthopaedic Institute, Research Center, Tucson, Arizona, USAOsteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying", with symptomatic control aiming to stave off the final solution of total joint replacement. Regenerative medicine and use of mesenchymal stem cells (MSC) promised hope to change that but have so far fallen short. This review focuses on current knowledge and use of MSC in clinic, completed research, and future directions for development of this once so promising biological treatment. Powerful treatment for pain in form of monoclonal antibodies against Nerve Growth Factor (NGF) are getting close to FDA approval in the US. Wnt signaling pathway modulators that decrease inflammation, increase function and potential to regenerate cartilage should be presented to the FDA early next year.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003181S.pdfosteoarthritismesenchymal stem cellswnt pathwayngf antibodies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Skrepnik Nebojša |
spellingShingle |
Skrepnik Nebojša Therapies for osteoarthritis today and tomorrow: Review Scripta Medica osteoarthritis mesenchymal stem cells wnt pathway ngf antibodies |
author_facet |
Skrepnik Nebojša |
author_sort |
Skrepnik Nebojša |
title |
Therapies for osteoarthritis today and tomorrow: Review |
title_short |
Therapies for osteoarthritis today and tomorrow: Review |
title_full |
Therapies for osteoarthritis today and tomorrow: Review |
title_fullStr |
Therapies for osteoarthritis today and tomorrow: Review |
title_full_unstemmed |
Therapies for osteoarthritis today and tomorrow: Review |
title_sort |
therapies for osteoarthritis today and tomorrow: review |
publisher |
Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine |
series |
Scripta Medica |
issn |
2490-3329 2303-7954 |
publishDate |
2020-01-01 |
description |
Osteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying", with symptomatic control aiming to stave off the final solution of total joint replacement. Regenerative medicine and use of mesenchymal stem cells (MSC) promised hope to change that but have so far fallen short. This review focuses on current knowledge and use of MSC in clinic, completed research, and future directions for development of this once so promising biological treatment. Powerful treatment for pain in form of monoclonal antibodies against Nerve Growth Factor (NGF) are getting close to FDA approval in the US. Wnt signaling pathway modulators that decrease inflammation, increase function and potential to regenerate cartilage should be presented to the FDA early next year. |
topic |
osteoarthritis mesenchymal stem cells wnt pathway ngf antibodies |
url |
https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003181S.pdf |
work_keys_str_mv |
AT skrepniknebojsa therapiesforosteoarthritistodayandtomorrowreview |
_version_ |
1724450736776937472 |